Health-related quality of life and symptom research in glioblastoma multiforme patients

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 5, Issue 6, 2005, Pages 763-774

  Taphoorn, Martin J B ^a   Bottomley, Andrew ^b  

^a MEDICAL CENTER HAAGLANDEN   (Netherlands)

^b EORTC DATA CENTER   (Belgium)

Author keywords

Cognition; Glioblastoma; Health related quality of life; Neurosurgery; Radiotherapy; Temozolomide

Indexed keywords

ANTICONVULSIVE AGENT; ANTINEOPLASTIC AGENT; CORTICOSTEROID; LOMUSTINE; NITROSOUREA; PROCARBAZINE; TEMOZOLOMIDE;

BRACHYTHERAPY; BRAIN EDEMA; CANCER GROWTH; CANCER RESEARCH; CANCER SURVIVAL; CLINICAL FEATURE; CLINICAL TRIAL; COGNITION; DRUG ANTAGONISM; GLIOBLASTOMA; HUMAN; MORBIDITY; PROGNOSIS; QUALITY OF LIFE; REVIEW; SIDE EFFECT; SYMPTOM;

EID: 30344442781     PISSN: 14737167     EISSN: 17448379     Source Type: Journal    
DOI: 10.1586/14737167.5.6.763     Document Type: Review

References (87)

1. Macdonald DR, Kiebert G, Prados M, Yung A, Olson J. Benefit of temozolomide compared to procarbazine in treatment of glioblastoma multiforme at first relapse: effect on neurological functioning, performance status, and health related quality of life. Cancer Invest. 23, 138-144 (2005).
2. Sanders C, Egger M, Donovan J et al. Reporting on quality of life in randomised controlled trials: bibliographic study. Br. Med. J. 317, 1191-1194 (1998).
3. Karnofsky DA, Burchenal JH. The clinical evaluation of chemotherapeutic agents in cancer. In: Evaluation of Chemotherapeutic Agents. Macleod CM (Ed.), Columbia University Press, NY, USA 191-205 (1949).
4. Efficace F, Bottomley A. Assessing HRQOL: a neglected issue for high-grade glioma. Lancet Oncol. 4, 11-12 (2003).
5. Aiken RD. Quality-of-life issues in patients with malignant gliomas. Sem. Oncol. 21, 273-275 (1994).
6. Heimans JJ, Taphoorn MJB. Impact of brain tumour treatment on quality of life. J. Neurol. 249, 955-960 (2002).
7. DeAngelis LM. Brain tumors. N. Engl. J. Med. 344, 114-123 (2001).
8. Smith JS, Perry A, Borell TJ et al. Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas and mixed oligoastrocytomas. J. Clin. Oncol. 18, 636-645 (2000).
9. Louis DN, Holland EG, Cairncross JG. Glioma classification: a molecular reappraisal. Am. J. Pathol. 159, 770-786 (2001).
10. Hegi ME, Diserens A-C, Gorlia T et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl. J. Med. 352, 997-1003 (2005).
11. Cairncross JG, Macdonald DR. Successful chemotherapy for recurrent malignant oligodendroglioma. Ann. Neurol. 23, 360-364 (1988).
12. Van den Bent MJ, Kros JM, Heimans JJ et al. Response rate and prognostic factors of recurrent oligodendroglioma treated with PCV chemotherapy. Neurology 51, 1140-1145 (1998).
13. Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 352, 987-996 (2005).
14. Bottomley A, Taphoorn MJ, Coens C et al. Predicting survival using health-related quality of life scores in glioblastoma cancer: findings from an international Phase III randomized controlled trial. 41th Annual Meeting of the American Society of Clinical Oncology (ASCO), FL, USA. J. Clin. Oncol. 23(16S), 861 (2003).
15. Kleihues P, Cavenee WK. In: Pathology and Genetics of Tumours of the Nervous System. IARC Press, Lyon, France (2000).
16. Davies E, Clarke C. Early symptoms of brain tumours. J. Neurol. Neurosurg. Psychiatry 75, 1205-1206 (2004).
17. Kreth FW, Berlis A, Spiropoulou V et al. The role of tumor resection in the treatment of glioblastoma multiforme in adults. Cancer 86, 2117-2123 (1999).
18. Lacroix M, Abi-Said D, Fourney DR et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J. Neurosurg. 95, 190-198 (2001).
19. Walker MD, Green SB, Byar DP et al. Randomized comparisons of radiotherapy and nitrosureas for the treatment of malignant glioma after surgery. N. Engl. J. Med. 303, 1323-1329 (1980).
20. Kristiansen K, Hagen S, Kolleveld T et al. Combined modality therapy of operated astrocytomas grade III and IV. Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time. Cancer 47, 649-652 (1981).
21. Slotman BJ, Kralendonk JH, van Alphen HAM et al. Hypofractionated radiation therapy in patients with glioblastoma multiforme: results of treatment and impact of prognostic factors. Int. J. Radiat. Oncol. Biol. Phys. 34, 895-898 (1996).
22. Roa W, Brasher PM, Bauman G et al. Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial. Int. J. Radiat. Oncol. Biol. Phys. 22, 1583-1588 (2004).
23. Stewart LA. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 23, 1011-1018 (2002).
24. Taphoorn MJB, Stupp R, Coens C et al. Health-related quality of life in patients with glioblastoma: a randomised controlled trial. Lancet Oncol. (2005) (In Press).
25. Straathof CS, van den Bent MJ, Schmitz PL et al. The effect of dexamethasone on the uptake of cisplatin in glioma and the area of brain around tumor. J. Neurooncol. 37, 1-8 (1998).
26. Vecht CJ, Wagner GL, Wilms EB. Interactions between anti-epileptic and chemotherapeutic drugs. Lancet Neurol. 2, 404-409 (2003).
27. Gupta T, Sarin R. Poor-prognosis high-grade gliomas: evolving an evidence-based standard care. Lancet Oncol. 3, 557-564 (2002).
28. Remer S, Murphy ME. The challenges of long-term treatment outcomes in adults with malignant gliomas. Clin. J. Oncol. Nurs. 8, 368-376 (2004).
29. Curran WJ Jr, Scott CB, Horton J et al. Recursive partitioning analysis of prognostic factors in three RTOG malignant glioma trials. J. Natl Cancer Instit. 85, 704-710 (1993).
30. Buckner JC. Factors influencing survival in high-grade gliomas. Semin. Oncol. 30, S19, 10-14 (2003).
31. Olson JD, Riedel E, DeAngelis LM. Long-term outcome of low-grade oligodendroglioma and mixed glioma. Neurology 54, 1442-1448 (2000).
32. Meyers CA, Hess KR, Yung WK, Levin VA. Cognitive function as a predictor of survival in patients with recurrent malignant glioma. J. Clin. Oncol. 18, 646-650 (2000).
33. Klein M, Postma TJ, Taphoorn MJB et al. The prognostic value of cognitive functioning in the survival of patients with high-grade glioma. Neurology 61, 1796-1799 (2003).
34. Sehlen S, Lenk M, Hollenhorst H et al. Quality of life as predictive mediator variable for survival in patients with intracerebral neoplasma during radiotherapy. Onkolegie 26, 38-43 (2003).
35. Taphoorn MJB, Klein M. Cognitive deficits in adult patients with brain tumours. Lancet Neurol. 3, 159-168 (2004).
36. Hahn CA, Dunn RH, Logue PE, King JH, Edwards CL, Halperin EC. Prospective study of neuropsychologic testing and quality-of-life assessment of adults with primary malignant brain tumors. Int. J. Radiat. Oncol. Biol. Phys. 55, 992-999 (2003).
37. Anderson SW, Damasio H, Tranel D. Neuropsychological impairment associated with lesions caused by tumor or stroke. Arch. Neurol. 47, 397-405 (1990).
38. Meyers CA, Hess KR. Multifaceted end points in brain tumor clinical trials: cognitive deterioration precedes MRI progression. Neuro. Oncol. 5, 89-95 (2003).
39. Klein M, Heimans JJ, Aaronson NK et al. Mid- to long-term cognitive sequelae in low-grade gliomas: the impact of radiotherapy and other treatment-related factors. Lancet 360, 1361-1368 (2002).
40. Macdonald DR, Cascino TL, Schold SC et al. Response criteria for Phase II studies of supratentorial malignant glioma. J. Clin. Oncol. 8, 1277-1280 (1990).
41. Clyde Z, Chataway SJ, Signorini D, Gregor A, Grant R. Significant change in tests of neurological impairment in patients with brain tumours. J. Neurooncol. 39, 81-90 (1998).
42. De Haan R, Limburg M, Schuling J et al. Clinimetric evaluation of the Barthel Index, a measure of limitations in daily activities. Ned. Tijdschr. Geneeskd. 137, 917-921 (1993).
43. Van Swieten JC, Koudstaal PJ, Visser MC, Schouten HC, van Gijn J. Interobserver agreement for the assessment of handicap in stroke patients. Stroke 19, 604-607 (1988).
44. Aaronson NK. Quality of life: What is it? How should it be measured? Oncology 2, 69-74 (1988).
45. Sprangers MA, Aaronson NK. The role of healthcare providers and significant others in evaluating the quality of life of patients with chronic disease: a review. J. Clin. Epidemiol. 45, 743-760 (1992).
46. Spitzer WO, Dobson AJ, Hall J et al. Measuring the quality of life of cancer patients: a concise QL-index for use by physicians.J. Chron. Disease 34, 585-597 (1981).
47. Gill TM, Feinstein AR. A critical appraisal of the quality of quality-of-life measurements. JAMA 272, 619-626 (1994).
48. Aaronson NK, Ahmedzai S, Bergman B et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J. Natl. Cancer Inst. 85, 365-376 (1993).
49. Weitzner MA, Meyers CA, Gelke CK, Byrne KS, Cella DF, Levin VA. The functional assessment of cancer therapy (FACT) scale. Development of a brain subscale and revalidation of the general version (FACT-G) in patients with primary brain tumors. Cancer 75, 1151-1161 (1995).
50. Osoba D, Aaronson NK, Muller M et al. The development and psychometric validation of a brain cancer quality-of-life questionnaire for use in combination with general cancer-specific questionnaires. Qual. Life Res. 5, 139-150 (1996).
51. Fayers P, Bottomley A, EORTC Quality of Life Group, Quality of Life Unit. Quality of life research within the EORTC- the EORTC QLQ-C30. European Organisation for Research and Treatment of Cancer. Eur. J. Cancer 38, S4, 125-133 (2002).
52. Fayers P, Aaronson N, Bjordal K et al. EORTC QLQ-C30 In: Scoring Manual Third Edition. EORTC Publications, Belgium (2001).
53. Osoba D, Rodrigues G, Myles J et al. Interpreting the significance of changes in health-related quality-of-life scores. J. Clin. Oncol. 16, 139-144 (1998).
54. Murray KJ, Nelson DF, Scott C et al. Quality-adjusted survival analysis of malignant glioma. Patients treated with twice-daily radiation and carmustine: a report of RTOG 83-02. Int. J. Radiat. Oncol. Biol. Phys. 31, 453-459 (1995).
55. Recht L, Glantz M, Chamberlain M, Hsieh CC. Quantative measurement of quality outcome in malignant glioma patients using an independent living score (ILS). Assessment of a retrospective chart. J. Neurooncol. 61, 127-136 (2003).
56. Walker M, Brown J, Brown K, Gregor A, Whittle IR, Grant R. Practical problems with the collection and interpretation of serial quality of life assessments in patients with malignant glioma. J. Neurooncol. 63, 179-186 (2003).
57. Bottomley A, Flechtner H, Efficace F et al. on behalf of the European Organisation for Research and Treatment of Cancer (EORTC) Data Center and Quality of Life Group. Health related quality of life outcomes in cancer clinical trials. Eur. J. Cancer 41(12), 1697-1709 (2005).
58. Groenvold M, Petersen M, Aaronson NK et al. for the EORTC Quality of Life Group. The development of the EORTC QLQ-C15-PAL: a shortened questionnaire for cancer patients in palliative care. Eur. J. Cancer (2005) (In Press).
59. Davies E, Clarke C. Views of bereaved relatives about quality of survival after radiotherapy for malignant cerebral glioma. J. Neurol. Neurosurg. Psychiatry 76, 555-561 (2005).
60. Hochberg FH, Linggood R, Wolfson L et al. Quality and duration of survival in glioblastoma multiforme. JAMA 241, 1016 (1979).
61. Hochberg FH, Slotnick B. Neuropsychologic impairment in astrocytoma survivors. Neurology 30, 172-177 (1980).
62. Lieberman AN, Foo SH, Ransohoff J et al. Long-term survival among patients with malignant brain tumors. Neurosurgery 10, 450-453 (1982).
63. Maire JP, Coudin B, Guérin J, Caudry M. Neuropsychological impairment in adults with brain tumors. Am. J. Clin. Oncol. 10, 152-162 (1987).
64. Imperato JP, Paleologos NA, Vick NA. Effects of treatment on long-term survivors with malignant astrocytomas. Ann. Neurol. 28, 818-822 (1990).
65. Ammirati M, Vick N, Liao Y et al. Effect of the extent of surgical resection in survival and quality of life in patients with supratentorial glioblastomas and anaplastic astrocytomas. Neurosurgery 21, 201-206 (1987).
66. Leibel SA, Gutin PH, Wara WM et al. Survival and quality of life after interstitial implantation of removable high-activity Iodine-125 for the treatment of patients with recurrent malignant gliomas. Int. J. Radiat. Oncol. Biol. Phys. 17, 1129-1139 (1989).
67. Sachsenheimer W, Piotrowski W, Bimmler T. Quality of life in patients with intracranial tumors on the basis of Karnofsky's performance status. J. Neurooncol. 13, 177-181 (1992).
68. Kleinberg L, Wallner K, Malkin MG. Good performance status of long-term disease-free survivors of intracranial gliomas. Int. J. Radiat. Oncol. Biol. Phys. 26, 129-133 (1993).
69. Mackworth N, Fobair P, Prados MD. Quality of life self-reports from 200 brain tumor patients: comparisons with Karnofsky performance scores. J. Neurooncol. 14, 243-253 (1992).
70. Archibald YM, Lunn D, Ruttan LA et al. Cognitive funtioning in long-term survivors of high-grade glioma. J. Neurosurg. 80, 247-253 (1994).
71. Schmidinger M, Linzmayer L, Becherer A et al. Psychometric- and quality-of-life assessment in long-term glioblastoma survivors. J. Neurooncol. 63, 55-61 (2003).
72. Giovagnoli AR. Quality of life in patients with stable disease after surgery, radiotherapy, and chemotherapy for malignant brain tumor. J. Neurol. Neurosurg. Psychiatry 67, 358-363 (1999).
73. Klein M, Taphoorn MJB, Heimans JJ et al. Neurobehavioral status and health-related quality of life in newly diagnosed high-grade glioma patients. J. Clin. Oncol. 19, 4037-4047 (2001).
74. Salo J, Niemela A, Joukamaa M, Koivukangas J. Effect of brain tumour laterality on patients' perceived quality of life. J. Neurol. Neurosurg. Psychiatry 72, 373-377 (2002).
75. Osoba D, Aaronson NK, Muller M et al. Effect of neurological dysfunction on health-related quality of life in patients with high-grade malignant glioma. J. Neurooncol. 34, 263-278 (1997).
76. Lovely MP, Miaskowski C, Dodd M. Relationship between fatigue and quality of life in patients with glioblastoma multiforme. Oncol. Nurs. Forum 26, 921-925 (1999).
77. Osoba D, Brada M, Prados MD, Yung WK. Effect of disease burden on health-related quality of life in patients with malignant gliomas. Neuro. Oncol. 2, 221-228 (2000).
78. Giovagnoli AR, Silvani A, Colombo E, Boiardi A. Facets and determinants of quality of life in patients with recurrent high grade glioma. J. Neurol. Neurosurg. Psychiatry 76, 562-568 (2005).
79. Efficace F, Bottomley A. Health-related quality of life assessment methodology and reported outcomes in randomised controlled trials of primary brain cancer. Eur. J. Cancer 38, 1824-1831 (2002).
80. Trojanowski T, Peszynski J, Turowski K et al. Quality of survival of patients with brain gliomas treated with postoperative CCNU and radiation therapy. J. Neurosurg. 70, 18-23 (1989).
81. Souhami L, Seiferheld W, Brachman D et al. Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: report of RTOG 93-05 protocol. Int. J. Radiat. Oncol. Biol. Phys. 60, 853-860 (2004).
82. Taylor BV, Buckner JC, Cascino TL. Effects of radiation and chemotherapy on cognitive function in patients with high-grade glioma. J. Clin. Oncol. 16, 2195-2201 (1998).
83. Pickles T, Goodman GB, Rheaume DE et al. Pion radiation for high grade astrocytoma: results of a randomized study. Int. J. Radiat. Oncol. Biol. Phys. 37, 491-497 (1997).
84. Bampoe J, Laperriere N, Pintillie M, Glen J, Micallef J, Bernstein M. Quality of life in patients with glioblastoma multiforme participating in a randomized study of brachytherapy as a boost treatment. J. Neurosurg. 93, 917-926 (2000).
85. Yung WK, Albright RE, Olson J et al. A Phase II study of temozolomide versus procarbazine in patients with glioblastoma multiforme at first relapse. Br. J. Cancer 83, 588-593 (2000).
86. Osoba D, Brada M, Yung WKA, Prados MD. Health-related quality of life in patients treated with temozolomide versus procarbazine for recurrent glioblastoma multiforme. J. Clin. Oncol. 18, 1481-1491 (2000).
87. Brada M, Hoang-Xuan K, Rampling R et al. Multicenter Phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse. Ann. Oncol. 12, 259-266 (2001).